When: Confirmed daily close >$70.30 on volume >14M with MACD bullish cross AND RSI >55 sustained AND on! segment disclosure showing >15% of revenue at next earnings

Then: Consider adding to Overweight; do NOT initiate new exposure above $69.50

When: Daily close <$63.50 on volume >10M (structural break with conviction) AND Polymarket zero-hike probability drops below 70%, OR FDA menthol ban/nicotine cap announcement, OR confirmed dividend cut warning, OR Q3 2026 OCF prints below $2.5B with cigarette volume erosion beyond 5%

Then: Full exit immediately

When: $60.00 daily close on volume >15M

Then: Capitulation confirmed; full exit

HOLD with three specific guardrails: (1) tighten position sizing to max 3% of portfolio given negative OCF trajectory and negative book equity, (2) move stop to $63.40 to give 200 SMA room as support rather than placing stop inside noise, (3) set conditional re-evaluation trigger if Q3 OCF prints below $2.5 billion to break seasonal recovery thesis.

• Q1 2026 operating cash flow down 25% YoY—structural deceleration, not seasonal quirk
• Q2 OCF collapsed 78% sequentially from $3.27B in Q4 2025 to $719M
• TTM FCF of $9.04B vs $7.1B in dividends (127% coverage) is backward-looking; forward trajectory suggests 100% or worse within two quarters
• 93% market-implied probability of zero Fed cuts signals stagflationary-lite, not bullish tailwind for yield names
• 6.4% yield attracts yield-chasing capital with zero fundamental loyalty—vulnerability on rotation
• 50 SMA has capped price for six weeks and flattened from 70.30 to 69.97, indicating decelerating medium-term trend
• MACD line still negative at -0.09, cross above signal only two weeks old from extremely negative base—mean reversion, not new uptrend
• Bollinger middle dropped nearly 8% in six weeks; current setup is falling knife, not base building
• Polymarket pricing Big Tobacco pouch consolidation at 38-44%—coin flips, not consensus confirmation
• FDA lawsuit has binary downside; loss locks smoke-free pipeline and increases cigarette mix weight
• Forward P/E 11.75x implies 23% earnings growth; PEG at 2.66 suggests expectations may be optimistic
• Negative book value of -$2.67B against $24.6B debt is structural ceiling on further debt issuance for buybacks
• Current stop at $64.50 is only $1.50 below $66 entry (~0.9 ATR)—too tight for name with $1.65 ATR, will get whipsawed

→ vs aggressive: TTM FCF coverage of 127% is a backward-looking anchor; the deteriorating quarterly OCF trajectory (Q2 at $719M vs $3.27B in Q4 2025) suggests coverage could be 100% or worse within two quarters if trends continue

→ vs aggressive: 93% probability of zero Fed cuts is misread as one-way tailwind; stagflationary-lite signal means defensive flows support MO short-term but create violent rotation risk when growth names become attractive again

→ vs aggressive: Technical 'coiled spring' framing ignores six-week distribution pattern at 50 SMA; MACD still negative at -0.09, Bollinger middle down 8%, and 50 SMA flat/decoupling—pattern reads as failed bounce, not base building

→ vs aggressive: FDA lawsuit and pouch consolidation treated as asymmetric upside but Polymarket 38-44% is coin flip; Big Tobacco consolidation could mean MO being outbid as easily as MO being consolidator, and FDA loss case not priced at all

→ vs aggressive: Forward P/E of 11.75x requiring 23% earnings growth is optimistic; negative book value of -$2.67B is structural ceiling on debt capacity, not 'disciplined capital return'—manangement has exhausted equity cushion

HOLD MO as a defensive yield collection strategy with disciplined risk management: 3% position ceiling, stop moved to 63.50, conditional trim trigger at 70 on volume reclaim of 50 SMA, and reassessment trigger if Q3 OCF prints below 2.5 billion.

• 50 SMA has been capping price for six weeks with the SMA itself flattening - medium term trend has rolled over
• MACD cross is fresh, histogram expanding from deeply negative base
• Bollinger middle has dropped nearly 8% in six weeks
• 200 SMA rising and structural floor intact at 65
• 6.4% yield against 4.5% money market backdrop represents a real relative value gap
• TTM FCF coverage is 127%
• Q3 2025 OCF was 3.09 billion
• Q1 OCF down 25% YoY is a real cash flow signal, not merely seasonal artifact
• Stop at 64.50 is 0.9 ATR below entry with 1.65 ATR name - too tight, recommend 63.50 which sits below 200 SMA at 65 and Bollinger lower band at 63.39
• Position sizing ceiling of 3% of portfolio (not 3-4%)
• Catalyst calendar includes Q3 earnings in late October and FDA procedural milestones
• FDA lawsuit Polymarket probabilities around 40% are coin flips equally consistent with PMI or BAT as consolidator
• If MO rallies through 70 on volume and reclaims 50 SMA with MACD histogram staying positive, trim to 2% position
• If Q3 OCF prints below 2.5 billion, seasonal recovery thesis is broken and dividend coverage argument should be reassessed

→ vs aggressive: Coiled spring framing is wrong - this is consolidation not coiling; stock bounced off 200 SMA and is stuck between 68 and 70; MACD/RSI recovery is base-building, not compression before release

→ vs aggressive: Q1 OCF down 25% YoY is not just seasonal artifact like Q2; this is a real cash flow signal in a quarter without working capital distortions - dismissing it as noise is what got people blindsided on tobacco dividend cuts in prior cycles

→ vs aggressive: FDA probabilities around 40% are coin flips equally consistent with PMI or BAT being the consolidator, which would actually be bearish for MO's competitive position

→ vs aggressive: FDA lawsuit framing as asymmetric upside ignores the loss case entirely - if MO loses, on! pipeline stays locked and smoke-free narrative collapses

→ vs aggressive: 64.50 stop is too tight at 0.9 ATR below entry with 1.65 ATR; normal daily volatility will routinely test it and whipsaw the position before catalysts materialize

→ vs conservative: Macro stagflation lite interpretation reads too much into 93% market implied odds of zero cuts; could equally mean Fed is comfortable letting real rates stay positive because nominal growth is fine

→ vs conservative: Regime change risk is a 7% tail risk, not base case; don't optimize position for 7% tail at expense of 93% base case